Stefanie Costa Pinto Lopes

Dr. Stefanie Costa Pinto Lopes


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
GRGlenda Quaresma Ramos
Glenda Quaresma Ramos
RARENATA GALVAO DE AZEVEDO
RENATA GALVAO DE AZEVEDO
ASAndré Correa de Oliveira Sagat
André Correa de Oliveira Sagat
MCMaria Luiza Lima da Costa
Maria Luiza Lima da Costa
Felipe Moura Araujo SilvaFelipe Moura Araujo Silva
Felipe Moura Araujo Silva
Rosemary Aparecida RoqueRosemary Aparecida Roque
Rosemary Aparecida Roque
Background/Objectives: In the Brazilian Amazon, which accounts for over 99% of national malaria cases, 34,260 cases were reported as of August 2025, predominantly caused by Plasmodium vivax, responsible for 86.69% of the infections. The increasing resistance of the parasite to conventional therapies highlights the urgent need for novel control strategies, with essential oils and plant-derived substances emerging as promising alternatives. Methods: In this context, we evaluated the anti-Plasmodium potential of Piper alatipetiolatum essential oil and its major constituent 6-ishwarone against P. vivax, including cytotoxicity in Vero and PBMCs, molecular docking on dihydrofolate reductase (DHFR) and lactate dehydrogenase (LDH), and in silico pharmacokinetic profiling. Results: Both the oil and 6-ishwarone inhibited P. vivax dose-dependently (2.1 ± 1 to 100%), with IC50 values of 9.25 µg/mL and 3.93 µg/mL, respectively. Importantly, no cytotoxic effects were observed at 24 h, with cell viability ranging from 94.7% to 98.3%, highlighting the selectivity of these compounds towards the parasite over mammalian cells. Docking studies indicated selective binding of 6-ishwarone to DHFR (−7.7 kcal/mol; Ki = 2.27 µM) with key interactions (Trp816, Lys820, Tyr819, Asn823, Thr865), whereas binding to LDH was weaker (−6.2 kcal/mol; Ki = 28.10 µM), suggesting DHFR as the primary molecular target. In silico ADMET predictions and experimental data indicated favorable drug-like properties: TPSA = 20.23 Å2, moderate lipophilicity (LogP = 3.37), soluble (ESOL Log S = −3.58; Ali Log S = −3.89; Silicos-IT Log S = −2.84), high gastrointestinal absorption, BBB permeability (0.985), not a P-glycoprotein substrate (0.11), and low likelihood of CYP inhibition. Toxicity predictions showed non-mutagenic and non-hepatotoxic effects, low cardiotoxicity (hERG inhibition risk 0.08–0.32), low reproductive toxicity (0.03), moderate neurotoxicity (0.28), low acute toxicity (oral LD50 = 2.061 mol/kg), and low chronic toxicity (LOAEL = 1.995 log mg/kg/day). Conclusions: Together, these findings demonstrate that essential oil and 6-ishwarone of P. alatipetiolatum are selective, bioavailable, and promising natural leads for antimalarial drug development.

11 April 2026 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
CFCamila Fabbri
Camila Fabbri
PMPedro Henrique S. Marcon
Pedro Henrique S. Marcon
ASAline de Sousa Santiago
Aline de Sousa Santiago
CSCaroline Conceição Sousa
Caroline Conceição Sousa
HQHelenita Costa Quadros
Helenita Costa Quadros
SLStefanie Costa Pinto Lopes
Stefanie Costa Pinto Lopes
Here, we present the synthesis, characterization, and pharmacological evaluation of ruthenium complexes of broad-spectrum drug Atovaquone (ATV). Structure–activity relationships revealed key determinants for antiplasmodial activity, such as the importance of the oxidation state [Ru(III) versus Ru(II)] and of hydrophilic or lipophilic coligands. These complexes demonstrated broader activity against both asexual and sexual parasite stages than ATV. Due to this broader effect, complexes exhibited faster action in antiplasmodial activity than ATV. Ruthenium content from the complexes’ treatment gradually and selectively accumulates in the parasite cell milieu. Efficacy was assessed in vivo against asexual and sexual stages. Complexes were capable of blocking parasite transmission from humans to insects, and this was achieved for both gametocytes and oocyst stages, while ATV solely blocked oocysts. This is the first example of metal complexes inhibiting both asexual and sexual parasites with similar potency, broadly expanding the therapeutic utility of metalladrugs in medicinal chemistry.